Abstract: TH-PO637
Clinical Manifestation and Prognosis of Membranous Nephropathy in Patients with Primary Sjögren Syndrome
Session Information
- Glomerular Diseases: Epidemiology and Case Reports
November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Trials
Authors
- Hou, Fangxing, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
- Zou, Linfeng, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
- Shi, Xiaoxiao, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
- Xia, Peng, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
- Qin, Yan, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
- Chen, Limeng, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
Background
Glomerulonephropathy (GN) in primary Sjögren's syndrome (pSS) was rare. We aimed to compare the clinical features and prognosis between patients with membranous nephropathy and pSS (pSS-MN) and idiopathic MN (iMN) patients.
Methods
From January 1993 to September 2022, at Peking Union Medical College Hospital, we enrolled 96 pSS-MN patients diagnosed with renal pathology and the revised version of the American-European Consensus Group. The control group was 150 iMN patients diagnosed with renal pathology and positive serum anti-M-type phospholipase A2 receptor (PLA2R) antibody.
Results
Compared to the iMN patients, the pSS-MN patients were older, predominantly females (80.2% vs. 44.7%, P <0.05), with lower 24h urine proteins, higher serum IgG levels, more anemia, and hypocomplementemia. pSS-MN patients had lower ratios of positive serum anti-PLA2R antibody (34.0% vs. 59.1%) and positive tissue PLA2R antigen (65% vs. 87.3%) (both P <0.05). During the median time of 22 months, treated with a combination of glucocorticoids, immunosuppressive agents (cyclophosphamide, calcineurin inhibitors, tripterygium glycosides), or rituximab, the patient's eGFR remained normal. Moreover, the 24h urine proteins decreased from 3.1 g/d to 0.8 g/d.
Conclusion
We reported the largest cohort of pSS-MN patients displayed more pronounced immunological anomalies, with a lower prevalence of positive serum anti-PLA2R antibody and tissue PLA2R antigen than the iMN patients, and responded well to the treatment with stable eGFR.
Funding
- Government Support – Non-U.S.